Spots Global Cancer Trial Database for pegph20
Every month we try and update this database with for pegph20 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | NCT02921022 | Pancreatic Canc... Advanced Pancre... | Gemcitabine Nab-paclitaxel PEGPH20 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma | NCT03979066 | Pancreatic Duct... | Atezolizumab PEGPH20 | 18 Years - 99 Years | Columbia University | |
| Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors | NCT00834704 | Solid Tumor | PEGPH20 | 18 Years - | Halozyme Therapeutics | |
| Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | NCT02921022 | Pancreatic Canc... Advanced Pancre... | Gemcitabine Nab-paclitaxel PEGPH20 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer | NCT02910882 | Pancreatic Aden... | PEGylated Recom... Gemcitabine Radiation | - 90 Years | Scripps Health | |
| A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors | NCT02563548 | NSCLC Gastric Cancer | PEGPH20 Pembrolizumab | 18 Years - | Halozyme Therapeutics | |
| Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | NCT01453153 | Stage IV Pancre... | Gemcitabine PEGPH20 Placebo | 18 Years - | Halozyme Therapeutics | |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | NCT01839487 | Metastatic Panc... | PEGPH20 Nab-paclitaxel Gemcitabine Dexamethasone Enoxaparin | 18 Years - | Halozyme Therapeutics | |
| S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | NCT01959139 | Metastatic Panc... | PEGPH20 Oxaliplatin Leucovorin Irinotecan 5-fluorouracil | 18 Years - 75 Years | SWOG Cancer Research Network | |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | NCT01839487 | Metastatic Panc... | PEGPH20 Nab-paclitaxel Gemcitabine Dexamethasone Enoxaparin | 18 Years - | Halozyme Therapeutics | |
| Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors | NCT00834704 | Solid Tumor | PEGPH20 | 18 Years - | Halozyme Therapeutics | |
| Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors | NCT01170897 | Solid Tumor | PEGPH20 | 18 Years - | Halozyme Therapeutics | |
| Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors | NCT00834704 | Solid Tumor | PEGPH20 | 18 Years - | Halozyme Therapeutics | |
| PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma | NCT02487277 | Adenocarcinoma | PEGPH20 Gemcitabine Nab-paclitaxel | 18 Years - | University of California, San Francisco | |
| S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | NCT01959139 | Metastatic Panc... | PEGPH20 Oxaliplatin Leucovorin Irinotecan 5-fluorouracil | 18 Years - 75 Years | SWOG Cancer Research Network |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
